Pfizer Shot - Search News

Pfizer Lyme Disease Vaccine Shows 70% Efficacy

Digest more

· 14h · on MSN

Pfizer working for approval on new Lyme disease vaccine as expert says tick activity rising in New England

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease.

· 1d · on MSN

Pfizer to seek FDA approval for Lyme disease vaccine candidate despite trial miss

· 1d

Pfizer’s Lyme vaccine shows efficacy, but misses key statistical hurdle

· 1d

Pfizer Lyme Disease Vaccine Shows 70% Efficacy, But Misses Statistical Goal

Pfizer and Valneva said on Monday their Lyme disease vaccine showed more than 70% efficacy in a late-stage study, even as it missed its main goal.

· 1d

Pfizer says Lyme disease vaccine is holding promise

· 1d

Pfizer-Valneva Lyme vaccine shows more than 70% efficacy but misses key goal

Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.

CT Insider on MSN

Pfizer to seek FDA approval for Lyme vaccine as CT report shows ticks are more abundant than ever

The annual tick report shows Lone Star ticks have established populations along Connecticut's shoreline, raising the risk of the red-meat allergy caused by alpha-gal syndrome.

12h

Pfizer seeks approval for Lyme disease vaccine

Pfizer says it's going to seek approval for its Lyme disease vaccine. That's despite the shot failing a late-stage trial.

Fierce Biotech

Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push

Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal. | Pfizer and Valneva have blamed “fewer than anticipated” Lyme disease cases for the failure of their phase 3 trial to hit its key goal.